Eli Lilly, Drug Maker of Zepbound and Mounjaro, Reaches $1 Trillion in Value

The 150-year-old drugmaker is the first company in health care to hit the milestone.

News
RFK Jr. Walks a Tightrope on Trump Deal for Obesity Drugs

The weight loss medicines are proving to be a test case for Robert F. Kennedy Jr., the health secretary, in straddling divisions between his supporters and the president.

News
Pfizer to Acquire Obesity Drug Start-Up Metsera in $10 Billion Deal

The announcement of the deal signaled an end to the bidding war for Metsera between Pfizer and Novo Nordisk, the Danish maker of Ozempic and Wegovy.

News
What Trump’s New Drug Pricing Deal Means for People With Obesity

The president’s agreement with drug companies involves a range of prices, depending on dose, product and how you’re paying.

News
Trump Announces Deal to Drop Obesity Drug Prices to as Little as $150 a Month

President Trump announced a deal with Eli Lilly and Novo Nordisk to lower prices on hugely popular weight-loss drugs for Medicare, Medicaid and American patients who pay with their own money.

News
Targeting Hims & Hers, F.D.A. Takes on a New Type of Drug Advertiser

Regulators sent about 100 warning letters this week to drug advertisers, including to Hims & Hers, a major online provider of weight-loss drugs.

News
Trump Moves to Crack Down on Drug Advertising

The administration is proposing a return to a 1990s-era policy that kept most drug ads off TV. That could dent the revenues of drugmakers and major networks.

News
Pill Causes Major Weight Loss in Eli Lilly Trial’s Results

The company said it planned to seek Food and Drug Administration approval for the drug, orforglipron, before the end of the year.

News
India, Once America’s Counterweight to China, Is Now Facing Trump’s Wrath

With threats of tariffs up to 50 percent, President Trump seems to be scrapping America’s plan to turn India into a counterweight to China, declaring instead that it is a “dead economy.”

News
Trump Demands That Drugmakers Lower Some of Their U.S. Prices by September

The administration has not put forward a clear legal authority to compel drugmakers to reduce their prices.

News